ArticleFrontiers in immunology2020

HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for "Off-the-Shelf" Immunotherapy.

Keven Hoerster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.